Literature DB >> 17276095

Recurrent varicose veins following surgical treatment: our experience with five years follow-up.

C Allegra1, P L Antignani, A Carlizza.   

Abstract

OBJECTIVE: To report the 5 year outcome of varicose veins surgery and to establish the factors determining recurrence. STUDY
DESIGN: Prospective observational study.
MATERIALS AND METHODS: This study reports the outcome in 1326 patients treated in a day surgery centre of an institutional referral centre. Patients were investigated clinically and by colour flow duplex scanning before operation. Treatments used included flush ligation of the sapheno-femoral junction (SFJ) and the sapheno-popliteal junction (SPJ). Incompetence of the great saphenous vein (GSV) and small saphenous vein (SSV) were managed by stripping of these veins. Perforating vein ligation and hook phlebectomy were also used. Patients were evaluated 3 weeks and 5 years following treatment by clinical examination and duplex ultrasonography.
RESULTS: 412 patients were excluded from the study because they failed to attend for follow-up or did not wear elastic stockings post-operatively. No residual saphenous truncal reflux was found at the initial assessment 3 weeks following surgery. After 5 years, recurrence of varicose veins occurred in 332 patients out of 1326 (25 %). Recurrences arose at the sapheno-femoral junction in 109 out of 862 patients (13%), at the sapheno-popliteal junction in 39 out of 132 patients (30%), in both saphenous regions 38 out of 107 patients (36%) and in 146 out of 225 subjects (65 %) with secondary varicose veins.
CONCLUSION: Varicose veins recurred despite technically correct surgery confirmed on post-operative duplex ultrasonography. The likelihood of recurrence increased in the presence of SSV reflux, perforating vein incompetence and post-thrombotic deep vein incompetence.

Entities:  

Mesh:

Year:  2007        PMID: 17276095     DOI: 10.1016/j.ejvs.2006.12.020

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  12 in total

Review 1.  [Diagnosis and treatment of varicose veins: part 2: therapeutic procedures and results].

Authors:  H Nüllen; T Noppeney
Journal:  Chirurg       Date:  2010-12       Impact factor: 0.955

Review 2.  Significance of Reflux Abolition at the Saphenofemoral Junction in Connection with Stripping and Ablative Methods.

Authors:  Cestmir Recek
Journal:  Int J Angiol       Date:  2015-03-23

3.  The hemodynamic paradox as a phenomenon triggering recurrent reflux in varicose vein disease.

Authors:  Cestmir Recek
Journal:  Int J Angiol       Date:  2012-09

Review 4.  The state of the art of endothermal ablation.

Authors:  Renate R van den Bos; Thomas M Proebstle
Journal:  Lasers Med Sci       Date:  2014-03       Impact factor: 3.161

5.  [Modern varicose vein surgery].

Authors:  G Bruning; B Altmann
Journal:  Hautarzt       Date:  2011-05       Impact factor: 0.751

6.  Treatment Patterns and Outcomes in Patients with Varicose Veins.

Authors:  Rajiv Mallick; Aditya Raju; Chelsey Campbell; Rashad Carlton; David Wright; Kimberly Boswell; Michael Eaddy
Journal:  Am Health Drug Benefits       Date:  2016-11

Review 7.  Calf pump activity influencing venous hemodynamics in the lower extremity.

Authors:  Cestmir Recek
Journal:  Int J Angiol       Date:  2013-03

8.  Treatment of varicose veins.

Authors:  Raha Nael; Suman Rathbun
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-04

9.  Assessment of causes and patterns of recurrent varicose veins after surgery.

Authors:  Mohammed A Gad; Aly Saber; Emad N Hokkam
Journal:  N Am J Med Sci       Date:  2012-01

10.  Mechanochemical endovenous ablation versus radiofrequency ablation in the treatment of primary small saphenous vein insufficiency (MESSI trial): study protocol for a randomized controlled trial.

Authors:  Doeke Boersma; Ramon R J P van Eekeren; Hans J C Kelder; Debora A B Werson; Suzanne Holewijn; Michiel A Schreve; Michel M P J Reijnen; Jean Paul P M de Vries
Journal:  Trials       Date:  2014-10-29       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.